ID   RXRA_HUMAN              Reviewed;         462 AA.
AC   P19793; B3KY83; Q2NL52; Q2V504;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   10-MAY-2017, entry version 205.
DE   RecName: Full=Retinoic acid receptor RXR-alpha;
DE   AltName: Full=Nuclear receptor subfamily 2 group B member 1;
DE   AltName: Full=Retinoid X receptor alpha;
GN   Name=RXRA; Synonyms=NR2B1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=2159111; DOI=10.1038/345224a0;
RA   Mangelsdorf D.J., Ong E.S., Dyck J.A., Evans R.M.;
RT   "Nuclear receptor that identifies a novel retinoic acid response
RT   pathway.";
RL   Nature 345:224-229(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND DNA-BINDING.
RX   PubMed=18619963; DOI=10.1016/j.febslet.2008.07.003;
RA   Kobayashi T., Kodani Y., Nozawa A., Endo Y., Sawasaki T.;
RT   "DNA-binding profiling of human hormone nuclear receptors via
RT   fluorescence correlation spectroscopy in a cell-free system.";
RL   FEBS Lett. 582:2737-2744(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 11-462.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   IDENTIFICATION OF LIGAND.
RX   PubMed=1310260; DOI=10.1016/0092-8674(92)90479-V;
RA   Heyman R.A., Mangelsdorf D.J., Dyck J.A., Stein R.B., Eichele G.,
RA   Evans R.M., Thaller C.;
RT   "9-cis retinoic acid is a high affinity ligand for the retinoid X
RT   receptor.";
RL   Cell 68:397-406(1992).
RN   [9]
RP   INTERACTION WITH NCOA3.
RX   PubMed=9267036; DOI=10.1016/S0092-8674(00)80516-4;
RA   Chen H., Lin R.J., Schiltz R.L., Chakravarti D., Nash A., Nagy L.,
RA   Privalsky M.L., Nakatani Y., Evans R.M.;
RT   "Nuclear receptor coactivator ACTR is a novel histone
RT   acetyltransferase and forms a multimeric activation complex with P/CAF
RT   and CBP/p300.";
RL   Cell 90:569-580(1997).
RN   [10]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10567404; DOI=10.1074/jbc.274.48.34283;
RA   Lee S.-K., Anzick S.L., Choi J.-E., Bubendorf L., Guan X.-Y.,
RA   Jung Y.-K., Kallioniemi O.-P., Kononen J., Trent J.M., Azorsa D.,
RA   Jhun B.-H., Cheong J.H., Lee Y.C., Meltzer P.S., Lee J.W.;
RT   "A nuclear factor ASC-2, as a cancer-amplified transcriptional
RT   coactivator essential for ligand-dependent transactivation by nuclear
RT   receptors in vivo.";
RL   J. Biol. Chem. 274:34283-34293(1999).
RN   [11]
RP   HETERODIMERIZATION WITH PPARA, AND FUNCTION.
RX   PubMed=10195690; DOI=10.1016/S0303-7207(98)00217-2;
RA   Gorla-Bajszczak A., Juge-Aubry C., Pernin A., Burger A.G., Meier C.A.;
RT   "Conserved amino acids in the ligand-binding and tau(i) domains of the
RT   peroxisome proliferator-activated receptor alpha are necessary for
RT   heterodimerization with RXR.";
RL   Mol. Cell. Endocrinol. 147:37-47(1999).
RN   [12]
RP   PHOSPHORYLATION AT SER-27, FUNCTION, AND MUTAGENESIS OF SER-27.
RX   PubMed=11162439; DOI=10.1006/bbrc.2000.4043;
RA   Harish S., Ashok M.S., Khanam T., Rangarajan P.N.;
RT   "Serine 27, a human retinoid X receptor alpha residue, phosphorylated
RT   by protein kinase A is essential for cyclicAMP-mediated downregulation
RT   of RXRalpha function.";
RL   Biochem. Biophys. Res. Commun. 279:853-857(2000).
RN   [13]
RP   INTERACTION WITH SFPQ.
RX   PubMed=11259580; DOI=10.1128/MCB.21.7.2298-2311.2001;
RA   Mathur M., Tucker P.W., Samuels H.H.;
RT   "PSF is a novel corepressor that mediates its effect through Sin3A and
RT   the DNA binding domain of nuclear hormone receptors.";
RL   Mol. Cell. Biol. 21:2298-2311(2001).
RN   [14]
RP   INTERACTION WITH HCV CORE PROTEIN AND PPARA, SUBCELLULAR LOCATION, AND
RP   FUNCTION.
RX   PubMed=11915042; DOI=10.1053/jhep.2002.32470;
RA   Tsutsumi T., Suzuki T., Shimoike T., Suzuki R., Moriya K.,
RA   Shintani Y., Fujie H., Matsuura Y., Koike K., Miyamura T.;
RT   "Interaction of hepatitis C virus core protein with retinoid X
RT   receptor alpha modulates its transcriptional activity.";
RL   Hepatology 35:937-946(2002).
RN   [15]
RP   INTERACTION WITH PRMT2.
RX   PubMed=12039952; DOI=10.1074/jbc.M201053200;
RA   Qi C., Chang J., Zhu Y., Yeldandi A.V., Rao S.M., Zhu Y.-J.;
RT   "Identification of protein arginine methyltransferase 2 as a
RT   coactivator for estrogen receptor alpha.";
RL   J. Biol. Chem. 277:28624-28630(2002).
RN   [16]
RP   INTERACTION WITH DNTTIP2.
RX   PubMed=15047147; DOI=10.1016/j.bbrc.2004.02.179;
RA   Bu H., Kashireddy P., Chang J., Zhu Y.T., Zhang Z., Zheng W.,
RA   Rao S.M., Zhu Y.-J.;
RT   "ERBP, a novel estrogen receptor binding protein enhancing the
RT   activity of estrogen receptor.";
RL   Biochem. Biophys. Res. Commun. 317:54-59(2004).
RN   [17]
RP   INTERACTION WITH RNF8.
RX   PubMed=14981089; DOI=10.1074/jbc.M309148200;
RA   Takano Y., Adachi S., Okuno M., Muto Y., Yoshioka T.,
RA   Matsushima-Nishiwaki R., Tsurumi H., Ito K., Friedman S.L.,
RA   Moriwaki H., Kojima S., Okano Y.;
RT   "The RING finger protein, RNF8, interacts with retinoid X receptor
RT   alpha and enhances its transcription-stimulating activity.";
RL   J. Biol. Chem. 279:18926-18934(2004).
RN   [18]
RP   INTERACTION WITH PELP1.
RX   PubMed=16574651; DOI=10.1074/jbc.M601593200;
RA   Singh R.R., Gururaj A.E., Vadlamudi R.K., Kumar R.;
RT   "9-cis-retinoic acid up-regulates expression of transcriptional
RT   coregulator PELP1, a novel coactivator of the retinoid X receptor
RT   alpha pathway.";
RL   J. Biol. Chem. 281:15394-15404(2006).
RN   [19]
RP   SUMOYLATION AT LYS-108, AND INTERACTION WITH SENP6.
RX   PubMed=16912044; DOI=10.1074/jbc.M604033200;
RA   Choi S.J., Chung S.S., Rho E.J., Lee H.W., Lee M.H., Choi H.S.,
RA   Seol J.H., Baek S.H., Bang O.S., Chung C.H.;
RT   "Negative modulation of RXRalpha transcriptional activity by small
RT   ubiquitin-related modifier (SUMO) modification and its reversal by
RT   SUMO-specific protease SUSP1.";
RL   J. Biol. Chem. 281:30669-30677(2006).
RN   [20]
RP   HETERODIMERIZATION WITH RARA.
RX   PubMed=17205979; DOI=10.1074/mcp.M600223-MCP200;
RA   Huq M.D., Tsai N.-P., Khan S.A., Wei L.-N.;
RT   "Lysine trimethylation of retinoic acid receptor-alpha: a novel means
RT   to regulate receptor function.";
RL   Mol. Cell. Proteomics 6:677-688(2007).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   INTERACTION WITH BHLHE40/DEC1; BHLHE41/DEC2; NCOA1; MED1; NCOR1 AND
RP   NCOR2.
RX   PubMed=19786558; DOI=10.1124/mol.109.057000;
RA   Cho Y., Noshiro M., Choi M., Morita K., Kawamoto T., Fujimoto K.,
RA   Kato Y., Makishima M.;
RT   "The basic helix-loop-helix proteins differentiated embryo chondrocyte
RT   (DEC) 1 and DEC2 function as corepressors of retinoid X receptors.";
RL   Mol. Pharmacol. 76:1360-1369(2009).
RN   [23]
RP   HETERODIMERIZATION WITH RARA, FUNCTION, AND MUTAGENESIS OF SER-27.
RX   PubMed=20215566; DOI=10.1210/en.2009-1338;
RA   Santos N.C., Kim K.H.;
RT   "Activity of retinoic acid receptor-alpha is directly regulated at its
RT   protein kinase A sites in response to follicle-stimulating hormone
RT   signaling.";
RL   Endocrinology 151:2361-2372(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-129, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-259, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   STRUCTURE BY NMR OF 130-223.
RX   PubMed=7925381; DOI=10.1111/j.1432-1033.1994.00639.x;
RA   Lee M.S., Sem D.S., Kliewer S.A., Provencal J., Evans R.M.,
RA   Wright P.E.;
RT   "NMR assignments and secondary structure of the retinoid X receptor
RT   alpha DNA-binding domain. Evidence for the novel C-terminal helix.";
RL   Eur. J. Biochem. 224:639-650(1994).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 130-209.
RX   PubMed=7746322; DOI=10.1038/375203a0;
RA   Rastinejad F., Perlmann T., Evans R.M., Sigler P.B.;
RT   "Structural determinants of nuclear receptor assembly on DNA direct
RT   repeats.";
RL   Nature 375:203-211(1995).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 225-462.
RX   PubMed=7760929; DOI=10.1038/375377a0;
RA   Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D.;
RT   "Crystal structure of the ligand-binding domain of the human nuclear
RT   receptor RXR-alpha.";
RL   Nature 375:377-382(1995).
RN   [30]
RP   STRUCTURE BY NMR OF 130-212.
RX   PubMed=9698548; DOI=10.1006/jmbi.1998.1908;
RA   Holmbeck S.M., Foster M.P., Casimiro D.R., Sem D.S., Dyson H.J.,
RA   Wright P.E.;
RT   "High-resolution solution structure of the retinoid X receptor DNA-
RT   binding domain.";
RL   J. Mol. Biol. 281:271-284(1998).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 129-209 IN COMPLEX WITH RARA
RP   AND DNA.
RX   PubMed=10698945; DOI=10.1093/emboj/19.5.1045;
RA   Rastinejad F., Wagner T., Zhao Q., Khorasanizadeh S.;
RT   "Structure of the RXR-RAR DNA-binding complex on the retinoic acid
RT   response element DR1.";
RL   EMBO J. 19:1045-1054(2000).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 224-462 OF APO AND HOLO
RP   FORMS.
RX   PubMed=10835357; DOI=10.1093/emboj/19.11.2592;
RA   Egea P.F., Mitschler A., Rochel N., Ruff M., Chambon P., Moras D.;
RT   "Crystal structure of the human RXRalpha ligand-binding domain bound
RT   to its natural ligand: 9-cis retinoic acid.";
RL   EMBO J. 19:2592-2601(2000).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 225-462 OF APO AND HOLO
RP   FORMS.
RX   PubMed=10970886; DOI=10.1101/gad.802300;
RA   Gampe R.T. Jr., Montana V.G., Lambert M.H., Wisely G.B., Milburn M.V.,
RA   Xu H.E.;
RT   "Structural basis for autorepression of retinoid X receptor by
RT   tetramer formation and the AF-2 helix.";
RL   Genes Dev. 14:2229-2241(2000).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 129-212 IN COMPLEX WITH DNA.
RX   PubMed=10669605; DOI=10.1006/jmbi.1999.3457;
RA   Zhao Q., Chasse S.A., Devarakonda S., Sierk M.L., Ahvazi B.,
RA   Rastinejad F.;
RT   "Structural basis of RXR-DNA interactions.";
RL   J. Mol. Biol. 296:509-520(2000).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 225-462 IN COMPLEX WITH
RP   PPARG; COACTIVATOR NCOA1; RETINOIC ACID AND SYNTHETIC ANTIDIABETIC
RP   AGONISTS ROSIGLITAZONE AND GI262570.
RX   PubMed=10882139; DOI=10.1016/S1097-2765(00)80448-7;
RA   Gampe R.T. Jr., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K.,
RA   Milburn M.V., Kliewer S.A., Willson T.M., Xu H.E.;
RT   "Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the
RT   molecular basis of heterodimerization among nuclear receptors.";
RL   Mol. Cell 5:545-555(2000).
RN   [36]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 225-462 IN COMPLEX WITH PPARA
RP   OR PPARG; 9-CIS RETINOIC ACID; COACTIVATOR NCOA1 AND PPAR SYNTHETIC
RP   AGONIST GW409544.
RX   PubMed=11698662; DOI=10.1073/pnas.241410198;
RA   Xu H.E., Lambert M.H., Montana V.G., Plunket K.D., Moore L.B.,
RA   Collins J.L., Oplinger J.A., Kliewer S.A., Gampe R.T. Jr., McKee D.D.,
RA   Moore J.T., Willson T.M.;
RT   "Structural determinants of ligand binding selectivity between the
RT   peroxisome proliferator-activated receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:13919-13924(2001).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.96 ANGSTROMS) OF 227-458 IN COMPLEX WITH
RP   M.MUSCULUS NR1I13; R.NORVEGICUS NCOA2 AND AGONIST INSECTICIDE
RP   CONTAMINANT TCPOBOP.
RX   PubMed=15610733; DOI=10.1016/S1097-2765(04)00727-0;
RA   Suino K., Peng L., Reynolds R., Li Y., Cha J.Y., Repa J.J.,
RA   Kliewer S.A., Xu H.E.;
RT   "The nuclear xenobiotic receptor CAR: structural determinants of
RT   constitutive activation and heterodimerization.";
RL   Mol. Cell 16:893-905(2004).
CC   -!- FUNCTION: Receptor for retinoic acid. Retinoic acid receptors bind
CC       as heterodimers to their target response elements in response to
CC       their ligands, all-trans or 9-cis retinoic acid, and regulate gene
CC       expression in various biological processes. The RAR/RXR
CC       heterodimers bind to the retinoic acid response elements (RARE)
CC       composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. The high
CC       affinity ligand for RXRs is 9-cis retinoic acid. RXRA serves as a
CC       common heterodimeric partner for a number of nuclear receptors. In
CC       the absence of ligand, the RXR-RAR heterodimers associate with a
CC       multiprotein complex containing transcription corepressors that
CC       induce histone acetylation, chromatin condensation and
CC       transcriptional suppression. On ligand binding, the corepressors
CC       dissociate from the receptors and associate with the coactivators
CC       leading to transcriptional activation. The RXRA/PPARA heterodimer
CC       is required for PPARA transcriptional activity on fatty acid
CC       oxidation genes such as ACOX1 and the P450 system genes.
CC       {ECO:0000269|PubMed:10195690, ECO:0000269|PubMed:11162439,
CC       ECO:0000269|PubMed:11915042, ECO:0000269|PubMed:20215566}.
CC   -!- SUBUNIT: Homodimer. Heterodimer with RARA; required for ligand-
CC       dependent retinoic acid receptor transcriptional activity.
CC       Heterodimer with PPARA (via the leucine-like zipper in the LBD);
CC       the interaction is required for PPARA transcriptional activity.
CC       Also heterodimerizes with PPARG. Interacts with NCOA3 and NCOA6
CC       coactivators. Interacts with FAM120B (By similarity). Interacts
CC       with PELP1, SENP6, SFPQ, DNTTIP2 and RNF8. Interacts (via the DNA
CC       binding domain) with HCV core protein; the interaction enhances
CC       the transcriptional activities of the RXRA/RARA and the RXRA/PPARA
CC       heterodimers. Interacts with PRMT2. Interacts with ASXL1 (By
CC       similarity). Interacts with BHLHE40/DEC1, BHLHE41/DEC2, NCOR1 and
CC       NCOR2. Interacts in a ligand-dependent fashion with MED1 and
CC       NCOA1. {ECO:0000250, ECO:0000269|PubMed:10567404,
CC       ECO:0000269|PubMed:10669605, ECO:0000269|PubMed:10698945,
CC       ECO:0000269|PubMed:10882139, ECO:0000269|PubMed:11259580,
CC       ECO:0000269|PubMed:11698662, ECO:0000269|PubMed:11915042,
CC       ECO:0000269|PubMed:12039952, ECO:0000269|PubMed:14981089,
CC       ECO:0000269|PubMed:15047147, ECO:0000269|PubMed:15610733,
CC       ECO:0000269|PubMed:16574651, ECO:0000269|PubMed:16912044,
CC       ECO:0000269|PubMed:19786558, ECO:0000269|PubMed:9267036}.
CC   -!- INTERACTION:
CC       Q03463:- (xeno); NbExp=3; IntAct=EBI-78598, EBI-9159704;
CC       Q71SY5:MED25; NbExp=4; IntAct=EBI-78598, EBI-394558;
CC       Q15788:NCOA1; NbExp=10; IntAct=EBI-78598, EBI-455189;
CC       Q9JLI4:Ncoa6 (xeno); NbExp=2; IntAct=EBI-78598, EBI-286271;
CC       P27986:PIK3R1; NbExp=8; IntAct=EBI-78598, EBI-79464;
CC       P10276:RARA; NbExp=6; IntAct=EBI-78598, EBI-413374;
CC       P42224:STAT1; NbExp=2; IntAct=EBI-78598, EBI-1057697;
CC       P11473:VDR; NbExp=2; IntAct=EBI-78598, EBI-286357;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00407, ECO:0000269|PubMed:11915042}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P19793-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19793-2; Sequence=VSP_056565;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in liver, also found in lung,
CC       kidney and heart.
CC   -!- DOMAIN: Composed of three domains: a modulating N-terminal domain
CC       (AF1 domain), a DNA-binding domain and a C-terminal ligand-binding
CC       domain (AF2 domain).
CC   -!- PTM: Phosphorylated on serine and threonine residues mainly in the
CC       N-terminal modulating domain. Constiutively phosphorylated on Ser-
CC       21 in the presence or absence of ligand. Under stress conditions,
CC       hyperphosphorylated by activated JNK on Ser-56, Ser-70, Thr-82 and
CC       Ser-260 (By similarity). Phosphorylated on Ser-27, in vitro, by
CC       PKA. This phosphorylation is required for repression of cAMP-
CC       mediated transcriptional activity of RARA. {ECO:0000250,
CC       ECO:0000269|PubMed:11162439}.
CC   -!- PTM: Sumoylation negatively regulates transcriptional activity.
CC       Desumoylated specifically by SENP6. {ECO:0000269|PubMed:16912044}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR2
CC       subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/rxra/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Retinoid X receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Retinoid_X_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52773; CAA36982.1; -; mRNA.
DR   EMBL; AB307705; BAH02296.1; -; mRNA.
DR   EMBL; AK131192; BAG54745.1; -; mRNA.
DR   EMBL; AC156789; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL354796; CAH70571.1; -; Genomic_DNA.
DR   EMBL; AL669970; CAH70571.1; JOINED; Genomic_DNA.
DR   EMBL; AL669970; CAM45733.1; -; Genomic_DNA.
DR   EMBL; AL354796; CAM45733.1; JOINED; Genomic_DNA.
DR   EMBL; AL683798; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471090; EAW88123.1; -; Genomic_DNA.
DR   EMBL; BC110998; AAI10999.1; -; mRNA.
DR   EMBL; DQ303444; ABB96254.1; -; Genomic_DNA.
DR   CCDS; CCDS35172.1; -. [P19793-1]
DR   PIR; S09592; S09592.
DR   RefSeq; NP_001278850.1; NM_001291921.1. [P19793-2]
DR   RefSeq; NP_002948.1; NM_002957.5. [P19793-1]
DR   UniGene; Hs.590886; -.
DR   PDB; 1BY4; X-ray; 2.10 A; A/B/C/D=129-209.
DR   PDB; 1DSZ; X-ray; 1.70 A; B=129-212.
DR   PDB; 1FBY; X-ray; 2.25 A; A/B=224-462.
DR   PDB; 1FM6; X-ray; 2.10 A; A/U=225-462.
DR   PDB; 1FM9; X-ray; 2.10 A; A=225-462.
DR   PDB; 1G1U; X-ray; 2.50 A; A/B/C/D=225-462.
DR   PDB; 1G5Y; X-ray; 2.00 A; A/B/C/D=225-462.
DR   PDB; 1K74; X-ray; 2.30 A; A=225-462.
DR   PDB; 1LBD; X-ray; 2.70 A; A=201-460.
DR   PDB; 1MV9; X-ray; 1.90 A; A=223-462.
DR   PDB; 1MVC; X-ray; 1.90 A; A=223-462.
DR   PDB; 1MZN; X-ray; 1.90 A; A/C/E/G=223-462.
DR   PDB; 1R0N; X-ray; 2.60 A; A=130-206.
DR   PDB; 1RDT; X-ray; 2.40 A; A=225-462.
DR   PDB; 1RXR; NMR; -; A=130-212.
DR   PDB; 1XLS; X-ray; 2.96 A; A/B/C/D=227-458.
DR   PDB; 1XV9; X-ray; 2.70 A; A/C=227-462.
DR   PDB; 1XVP; X-ray; 2.60 A; A/C=227-462.
DR   PDB; 1YNW; X-ray; 3.00 A; B=130-228.
DR   PDB; 2ACL; X-ray; 2.80 A; A/C/E/G=225-462.
DR   PDB; 2NLL; X-ray; 1.90 A; A=135-200.
DR   PDB; 2P1T; X-ray; 1.80 A; A=223-462.
DR   PDB; 2P1U; X-ray; 2.20 A; A=223-462.
DR   PDB; 2P1V; X-ray; 2.20 A; A=223-462.
DR   PDB; 2ZXZ; X-ray; 3.00 A; A=223-462.
DR   PDB; 2ZY0; X-ray; 2.90 A; A/C=223-462.
DR   PDB; 3DZU; X-ray; 3.20 A; A=11-462.
DR   PDB; 3DZY; X-ray; 3.10 A; A=11-462.
DR   PDB; 3E00; X-ray; 3.10 A; A=11-462.
DR   PDB; 3E94; X-ray; 1.90 A; A=223-462.
DR   PDB; 3FAL; X-ray; 2.36 A; A/C=225-462.
DR   PDB; 3FC6; X-ray; 2.06 A; A/C=225-462.
DR   PDB; 3FUG; X-ray; 2.00 A; A=223-462.
DR   PDB; 3H0A; X-ray; 2.10 A; A=228-455.
DR   PDB; 3KWY; X-ray; 2.30 A; A=223-462.
DR   PDB; 3NSP; X-ray; 2.90 A; A/B=223-462.
DR   PDB; 3NSQ; X-ray; 2.60 A; A/B=223-462.
DR   PDB; 3OAP; X-ray; 2.05 A; A=228-458.
DR   PDB; 3OZJ; X-ray; 2.10 A; A/C=225-462.
DR   PDB; 3PCU; X-ray; 2.00 A; A=229-458.
DR   PDB; 3R29; X-ray; 2.90 A; A/B=223-462.
DR   PDB; 3R2A; X-ray; 3.00 A; A/B/C/D=223-462.
DR   PDB; 3R5M; X-ray; 2.80 A; A/C=223-462.
DR   PDB; 3UVV; X-ray; 2.95 A; B=225-462.
DR   PDB; 4CN2; X-ray; 2.07 A; C/D=130-212.
DR   PDB; 4CN3; X-ray; 2.35 A; A/B/C=130-212, D=130-173, D=175-212.
DR   PDB; 4CN5; X-ray; 2.00 A; A/B=130-212.
DR   PDB; 4CN7; X-ray; 2.34 A; A/B/E/F=130-212.
DR   PDB; 4J5W; X-ray; 2.80 A; C/D=227-462.
DR   PDB; 4J5X; X-ray; 2.80 A; C/D=227-462.
DR   PDB; 4K4J; X-ray; 2.00 A; A=228-458.
DR   PDB; 4K6I; X-ray; 2.10 A; A=228-458.
DR   PDB; 4M8E; X-ray; 2.40 A; A=228-458.
DR   PDB; 4M8H; X-ray; 2.20 A; A=228-458.
DR   PDB; 4N5G; X-ray; 2.11 A; A/B/C/D=223-462.
DR   PDB; 4N8R; X-ray; 2.03 A; A/B/C/D=223-462.
DR   PDB; 4NQA; X-ray; 3.10 A; A/H=98-462.
DR   PDB; 4OC7; X-ray; 2.50 A; A=223-462.
DR   PDB; 4POH; X-ray; 2.30 A; A=228-458.
DR   PDB; 4POJ; X-ray; 2.00 A; A=228-458.
DR   PDB; 4PP3; X-ray; 2.00 A; A=228-458.
DR   PDB; 4PP5; X-ray; 2.00 A; A=228-458.
DR   PDB; 4RFW; X-ray; 2.40 A; A=228-458.
DR   PDB; 4RMC; X-ray; 2.70 A; A=228-458.
DR   PDB; 4RMD; X-ray; 1.90 A; A=228-462.
DR   PDB; 4RME; X-ray; 2.30 A; A=228-462.
DR   PDB; 4ZO1; X-ray; 3.22 A; B=231-455.
DR   PDB; 4ZSH; X-ray; 1.80 A; A=223-462.
DR   PDB; 5EC9; X-ray; 2.30 A; A=229-456.
DR   PDBsum; 1BY4; -.
DR   PDBsum; 1DSZ; -.
DR   PDBsum; 1FBY; -.
DR   PDBsum; 1FM6; -.
DR   PDBsum; 1FM9; -.
DR   PDBsum; 1G1U; -.
DR   PDBsum; 1G5Y; -.
DR   PDBsum; 1K74; -.
DR   PDBsum; 1LBD; -.
DR   PDBsum; 1MV9; -.
DR   PDBsum; 1MVC; -.
DR   PDBsum; 1MZN; -.
DR   PDBsum; 1R0N; -.
DR   PDBsum; 1RDT; -.
DR   PDBsum; 1RXR; -.
DR   PDBsum; 1XLS; -.
DR   PDBsum; 1XV9; -.
DR   PDBsum; 1XVP; -.
DR   PDBsum; 1YNW; -.
DR   PDBsum; 2ACL; -.
DR   PDBsum; 2NLL; -.
DR   PDBsum; 2P1T; -.
DR   PDBsum; 2P1U; -.
DR   PDBsum; 2P1V; -.
DR   PDBsum; 2ZXZ; -.
DR   PDBsum; 2ZY0; -.
DR   PDBsum; 3DZU; -.
DR   PDBsum; 3DZY; -.
DR   PDBsum; 3E00; -.
DR   PDBsum; 3E94; -.
DR   PDBsum; 3FAL; -.
DR   PDBsum; 3FC6; -.
DR   PDBsum; 3FUG; -.
DR   PDBsum; 3H0A; -.
DR   PDBsum; 3KWY; -.
DR   PDBsum; 3NSP; -.
DR   PDBsum; 3NSQ; -.
DR   PDBsum; 3OAP; -.
DR   PDBsum; 3OZJ; -.
DR   PDBsum; 3PCU; -.
DR   PDBsum; 3R29; -.
DR   PDBsum; 3R2A; -.
DR   PDBsum; 3R5M; -.
DR   PDBsum; 3UVV; -.
DR   PDBsum; 4CN2; -.
DR   PDBsum; 4CN3; -.
DR   PDBsum; 4CN5; -.
DR   PDBsum; 4CN7; -.
DR   PDBsum; 4J5W; -.
DR   PDBsum; 4J5X; -.
DR   PDBsum; 4K4J; -.
DR   PDBsum; 4K6I; -.
DR   PDBsum; 4M8E; -.
DR   PDBsum; 4M8H; -.
DR   PDBsum; 4N5G; -.
DR   PDBsum; 4N8R; -.
DR   PDBsum; 4NQA; -.
DR   PDBsum; 4OC7; -.
DR   PDBsum; 4POH; -.
DR   PDBsum; 4POJ; -.
DR   PDBsum; 4PP3; -.
DR   PDBsum; 4PP5; -.
DR   PDBsum; 4RFW; -.
DR   PDBsum; 4RMC; -.
DR   PDBsum; 4RMD; -.
DR   PDBsum; 4RME; -.
DR   PDBsum; 4ZO1; -.
DR   PDBsum; 4ZSH; -.
DR   PDBsum; 5EC9; -.
DR   DisProt; DP00062; -.
DR   ProteinModelPortal; P19793; -.
DR   SMR; P19793; -.
DR   BioGrid; 112168; 116.
DR   DIP; DIP-641N; -.
DR   IntAct; P19793; 42.
DR   MINT; MINT-98407; -.
DR   STRING; 9606.ENSP00000419692; -.
DR   BindingDB; P19793; -.
DR   ChEMBL; CHEMBL2061; -.
DR   DrugBank; DB07863; 2-chloro-5-nitro-N-phenylbenzamide.
DR   DrugBank; DB00459; Acitretin.
DR   DrugBank; DB00210; Adapalene.
DR   DrugBank; DB00523; Alitretinoin.
DR   DrugBank; DB00307; Bexarotene.
DR   DrugBank; DB00749; Etodolac.
DR   DrugBank; DB00926; Etretinate.
DR   DrugBank; DB08601; tributylstannanyl.
DR   GuidetoPHARMACOLOGY; 610; -.
DR   SwissLipids; SLP:000001552; -.
DR   iPTMnet; P19793; -.
DR   PhosphoSitePlus; P19793; -.
DR   BioMuta; RXRA; -.
DR   DMDM; 133701; -.
DR   EPD; P19793; -.
DR   MaxQB; P19793; -.
DR   PaxDb; P19793; -.
DR   PeptideAtlas; P19793; -.
DR   PRIDE; P19793; -.
DR   DNASU; 6256; -.
DR   Ensembl; ENST00000481739; ENSP00000419692; ENSG00000186350. [P19793-1]
DR   GeneID; 6256; -.
DR   KEGG; hsa:6256; -.
DR   UCSC; uc004cfb.3; human. [P19793-1]
DR   CTD; 6256; -.
DR   DisGeNET; 6256; -.
DR   GeneCards; RXRA; -.
DR   HGNC; HGNC:10477; RXRA.
DR   HPA; CAB004565; -.
DR   HPA; CAB005352; -.
DR   MIM; 180245; gene.
DR   neXtProt; NX_P19793; -.
DR   OpenTargets; ENSG00000186350; -.
DR   PharmGKB; PA34890; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   GeneTree; ENSGT00760000118948; -.
DR   HOVERGEN; HBG005606; -.
DR   InParanoid; P19793; -.
DR   KO; K08524; -.
DR   OMA; MDTKHFL; -.
DR   OrthoDB; EOG091G0YX6; -.
DR   PhylomeDB; P19793; -.
DR   TreeFam; TF352097; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-159418; Recycling of bile acids and salts.
DR   Reactome; R-HSA-192105; Synthesis of bile acids and bile salts.
DR   Reactome; R-HSA-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-HSA-193807; Synthesis of bile acids and bile salts via 27-hydroxycholesterol.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-200425; Import of palmitoyl-CoA into the mitochondrial matrix.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-204174; Regulation of pyruvate dehydrogenase (PDH) complex.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5362517; Signaling by Retinoic Acid.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   SignaLink; P19793; -.
DR   SIGNOR; P19793; -.
DR   ChiTaRS; RXRA; human.
DR   EvolutionaryTrace; P19793; -.
DR   GeneWiki; Retinoid_X_receptor_alpha; -.
DR   GenomeRNAi; 6256; -.
DR   PMAP-CutDB; P19793; -.
DR   PRO; PR:P19793; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000186350; -.
DR   CleanEx; HS_RXRA; -.
DR   ExpressionAtlas; P19793; baseline and differential.
DR   Genevisible; P19793; HS.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:CAFA.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0090575; C:RNA polymerase II transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0004886; F:9-cis retinoic acid receptor activity; TAS:ProtInc.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0050692; F:DBD domain binding; IDA:CAFA.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0003690; F:double-stranded DNA binding; IMP:CAFA.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0050693; F:LBD domain binding; IDA:CAFA.
DR   GO; GO:0016922; F:ligand-dependent nuclear receptor binding; IPI:CAFA.
DR   GO; GO:0042277; F:peptide binding; IDA:CAFA.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0001972; F:retinoic acid binding; IDA:CAFA.
DR   GO; GO:0003708; F:retinoic acid receptor activity; TAS:BHF-UCL.
DR   GO; GO:0044323; F:retinoic acid-responsive element binding; IDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0004879; F:RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:AgBase.
DR   GO; GO:0003707; F:steroid hormone receptor activity; IEA:InterPro.
DR   GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0042809; F:vitamin D receptor binding; IPI:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IDA:CAFA.
DR   GO; GO:0015721; P:bile acid and bile salt transport; TAS:Reactome.
DR   GO; GO:0043010; P:camera-type eye development; IEA:Ensembl.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0008203; P:cholesterol metabolic process; TAS:BHF-UCL.
DR   GO; GO:0007566; P:embryo implantation; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0001893; P:maternal placenta development; IEA:Ensembl.
DR   GO; GO:0019048; P:modulation by virus of host morphology or physiology; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0035357; P:peroxisome proliferator activated receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:1901522; P:positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus; IEA:Ensembl.
DR   GO; GO:0045994; P:positive regulation of translational initiation by iron; IEA:Ensembl.
DR   GO; GO:0051289; P:protein homotetramerization; IDA:MGI.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0048384; P:retinoic acid receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0060528; P:secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development; IEA:Ensembl.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0055012; P:ventricular cardiac muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0055010; P:ventricular cardiac muscle tissue morphogenesis; IEA:Ensembl.
DR   GO; GO:0006766; P:vitamin metabolic process; TAS:ProtInc.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR021780; Nuc_recep-AF1.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR000003; Retinoid-X_rcpt/HNF4.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF11825; Nuc_recep-AF1; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PRINTS; PR00545; RETINOIDXR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; DNA-binding;
KW   Host-virus interaction; Isopeptide bond; Metal-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    462       Retinoic acid receptor RXR-alpha.
FT                                /FTId=PRO_0000053566.
FT   DNA_BIND    135    200       Nuclear receptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   ZN_FING     135    155       NR C4-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   ZN_FING     171    195       NR C4-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   REGION        1    134       Modulating. {ECO:0000250}.
FT   REGION      201    224       Hinge.
FT   REGION      225    462       Ligand-binding.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P28700}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000269|PubMed:11162439}.
FT   MOD_RES      56     56       Phosphoserine; by MAPK8 and MAPK9.
FT                                {ECO:0000250}.
FT   MOD_RES      70     70       Phosphoserine; by MAPK8 and MAPK9.
FT                                {ECO:0000250}.
FT   MOD_RES      82     82       Phosphothreonine; by MAPK8 and MAPK9.
FT                                {ECO:0000250}.
FT   MOD_RES     129    129       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     259    259       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     260    260       Phosphoserine; by MAPK8 and MAPK9.
FT                                {ECO:0000250}.
FT   CROSSLNK    108    108       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:16912044}.
FT   VAR_SEQ       1     97       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056565.
FT   VARIANT     261    261       P -> L (in dbSNP:rs2234960).
FT                                /FTId=VAR_014620.
FT   VARIANT     327    327       A -> S (in dbSNP:rs1805345).
FT                                /FTId=VAR_050582.
FT   VARIANT     336    336       S -> I (in dbSNP:rs1805345).
FT                                /FTId=VAR_014621.
FT   VARIANT     398    398       A -> V (in dbSNP:rs11542209).
FT                                /FTId=VAR_050583.
FT   MUTAGEN      27     27       S->A: Abolishes phosphorylation. No
FT                                change in increase of RARA-mediated
FT                                transcriptional activity.
FT                                {ECO:0000269|PubMed:11162439,
FT                                ECO:0000269|PubMed:20215566}.
FT   MUTAGEN      27     27       S->A: Increase in RARA-mediated
FT                                transcriptional activity.
FT                                {ECO:0000269|PubMed:11162439,
FT                                ECO:0000269|PubMed:20215566}.
FT   STRAND      131    134       {ECO:0000244|PDB:4CN5}.
FT   TURN        136    138       {ECO:0000244|PDB:1DSZ}.
FT   STRAND      141    146       {ECO:0000244|PDB:1DSZ}.
FT   STRAND      149    151       {ECO:0000244|PDB:4CN5}.
FT   HELIX       153    165       {ECO:0000244|PDB:1DSZ}.
FT   STRAND      172    175       {ECO:0000244|PDB:2NLL}.
FT   TURN        181    186       {ECO:0000244|PDB:1DSZ}.
FT   HELIX       188    197       {ECO:0000244|PDB:1DSZ}.
FT   HELIX       202    204       {ECO:0000244|PDB:1DSZ}.
FT   HELIX       226    229       {ECO:0000244|PDB:3FC6}.
FT   HELIX       232    242       {ECO:0000244|PDB:2P1T}.
FT   HELIX       246    250       {ECO:0000244|PDB:1MZN}.
FT   TURN        251    253       {ECO:0000244|PDB:1FM9}.
FT   STRAND      258    261       {ECO:0000244|PDB:1XVP}.
FT   HELIX       264    284       {ECO:0000244|PDB:2P1T}.
FT   HELIX       289    291       {ECO:0000244|PDB:2P1T}.
FT   HELIX       294    316       {ECO:0000244|PDB:2P1T}.
FT   TURN        317    319       {ECO:0000244|PDB:2P1T}.
FT   STRAND      320    325       {ECO:0000244|PDB:2P1T}.
FT   TURN        327    329       {ECO:0000244|PDB:4N8R}.
FT   STRAND      331    333       {ECO:0000244|PDB:2P1T}.
FT   HELIX       334    338       {ECO:0000244|PDB:2P1T}.
FT   TURN        339    341       {ECO:0000244|PDB:2P1T}.
FT   HELIX       343    352       {ECO:0000244|PDB:2P1T}.
FT   HELIX       354    359       {ECO:0000244|PDB:2P1T}.
FT   HELIX       364    375       {ECO:0000244|PDB:2P1T}.
FT   STRAND      380    382       {ECO:0000244|PDB:3DZU}.
FT   HELIX       386    407       {ECO:0000244|PDB:2P1T}.
FT   HELIX       414    419       {ECO:0000244|PDB:2P1T}.
FT   HELIX       422    442       {ECO:0000244|PDB:2P1T}.
FT   STRAND      444    447       {ECO:0000244|PDB:4ZO1}.
FT   HELIX       449    454       {ECO:0000244|PDB:2P1T}.
FT   HELIX       457    459       {ECO:0000244|PDB:3NSQ}.
SQ   SEQUENCE   462 AA;  50811 MW;  7F952B580AD84C42 CRC64;
     MDTKHFLPLD FSTQVNSSLT SPTGRGSMAA PSLHPSLGPG IGSPGQLHSP ISTLSSPING
     MGPPFSVISS PMGPHSMSVP TTPTLGFSTG SPQLSSPMNP VSSSEDIKPP LGLNGVLKVP
     AHPSGNMASF TKHICAICGD RSSGKHYGVY SCEGCKGFFK RTVRKDLTYT CRDNKDCLID
     KRQRNRCQYC RYQKCLAMGM KREAVQEERQ RGKDRNENEV ESTSSANEDM PVERILEAEL
     AVEPKTETYV EANMGLNPSS PNDPVTNICQ AADKQLFTLV EWAKRIPHFS ELPLDDQVIL
     LRAGWNELLI ASFSHRSIAV KDGILLATGL HVHRNSAHSA GVGAIFDRVL TELVSKMRDM
     QMDKTELGCL RAIVLFNPDS KGLSNPAEVE ALREKVYASL EAYCKHKYPE QPGRFAKLLL
     RLPALRSIGL KCLEHLFFFK LIGDTPIDTF LMEMLEAPHQ MT
//
